Dexcom faces mounting scrutiny over G7 safety concerns, FDA violations, financial practices, and growing competition from Abbott's Libre 3.

Flavia Pease will take over as Insulet’s CFO on Sept. 30. Elsewhere, outgoing Dexcom CEO Kevin Sayer is taking a medical leave of absence.

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include ...

A continuous glucose monitor is a better option than pricking your finger daily. These wearable devices are stuck to your arm and connect to an app on your smartphone or Apple Watch to easily test ...

Dexcom today filed an SEC form to announce that Chair and CEO Kevin Sayer is taking a temporary medical leave of absence.

The Kaleido insulin patch pump worn on the arm. [Image courtesy of ViCentra] For ViCentra CEO Tom Arnold, the journey to lead a developer of insulin delivery technologies was a personal one. A veteran ...

Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on ...